The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Bruce R. Blazar

University of Minnesota Cancer Center

Minneapolis

MN 55455

USA

[email]@tc.umn.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • University of Minnesota Cancer Center, Minneapolis, MN 55455, USA. 2001 - 2006
  • University of Minnesota Cancer Center and Department of Pediatrics, Division of Bone Marrow Transplantation, Minneapolis, MN 55455, USA. 2001 - 2005

References

  1. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blazar, B.R., Weisdorf, D.J., Defor, T., Goldman, A., Braun, T., Silver, S., Ferrara, J.L. Blood (2006) [Pubmed]
  2. Regulatory T cells. Blazar, B.R., Taylor, P.A. Biol. Blood Marrow Transplant. (2005) [Pubmed]
  3. CD30/CD30 ligand (CD153) interaction regulates CD4+ T cell-mediated graft-versus-host disease. Blazar, B.R., Levy, R.B., Mak, T.W., Panoskaltsis-Mortari, A., Muta, H., Jones, M., Roskos, M., Serody, J.S., Yagita, H., Podack, E.R., Taylor, P.A. J. Immunol. (2004) [Pubmed]
  4. Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients. Blazar, B.R., Sharpe, A.H., Chen, A.I., Panoskaltsis-Mortari, A., Lees, C., Akiba, H., Yagita, H., Killeen, N., Taylor, P.A. Blood (2003) [Pubmed]
  5. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. Blazar, B.R., Carreno, B.M., Panoskaltsis-Mortari, A., Carter, L., Iwai, Y., Yagita, H., Nishimura, H., Taylor, P.A. J. Immunol. (2003) [Pubmed]
  6. Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients. Blazar, B.R., Kwon, B.S., Panoskaltsis-Mortari, A., Kwak, K.B., Peschon, J.J., Taylor, P.A. J. Immunol. (2001) [Pubmed]
  7. Flt3 ligand (FL) treatment of murine donors does not modify graft-versus-host disease (GVHD) but FL treatment of recipients post-bone marrow transplantation accelerates GVHD lethality. Blazar, B.R., McKenna, H.J., Panoskaltsis-Mortari, A., Taylor, P.A. Biol. Blood Marrow Transplant. (2001) [Pubmed]
  8. CD47 (integrin-associated protein) engagement of dendritic cell and macrophage counterreceptors is required to prevent the clearance of donor lymphohematopoietic cells. Blazar, B.R., Lindberg, F.P., Ingulli, E., Panoskaltsis-Mortari, A., Oldenborg, P.A., Iizuka, K., Yokoyama, W.M., Taylor, P.A. J. Exp. Med. (2001) [Pubmed]
 
WikiGenes - Universities